Skip to main content

Table 1 Baseline characteristics of patients with CPP and EP

From: Higher prevalence of obesity and overweight without an adverse metabolic profile in girls with central precocious puberty compared to girls with early puberty, regardless of GnRH analogue treatment

 

CPP

EP

p value

n

37

34

-

Treated/Untreated

29/8

14/20

-

Clinical characteristics

  

-

Chronological age (yr)

7.4 ± 1.3

8.8 ± 0.6

0.001

Bone age (yr)

8.7 ± 2.1

9.3 ± 1.3

NS

Weight (Kg)

32.1 ± 6.7

32.6 ± 4.4

NS

Weight (z-score)

1.4 ± 0.8

1.9 ± 1.2

0.001

Height (SDS)

2.8 ± 1.2

1.3 ± 1.1

0.001

BMI (Kg/m2)

18.8 ± 2.4

18.2 ± 2

NS

BMI (z-score)

1.1 ± 0.8

0.6 ± 0.7

0.004

Obesity/Overweight n(%)

27 (72.9)

12 (35.3)

0.001

Obesity n(%)

9 (24.3)

3 (8.8)

NS

Overweight n(%)

18 (48.6)

9 (26.5)

0.054

Predict adult height (SDS) (SDS) (SDS)

0.3 ± 2.3

1.5 ± 1.2

0.04

Height velocity (SDS)

1.6 ± 2.1

1.8 ± 1.8

NS

Hormonal evaluation

   

DHEAS (ng/ml)

51.1 ± 34.2

52.8 ± 23.7

NS

LH peak (IU/L)

10.9 ± 7.3

6.1 ± 4.5

0.01

LH to FSH stimulated ratio

1.1 ± 0.7

1.1 ± 1.7

NS

Estradiol (pg/ml)

22.3 ± 17

14 ± 11.8

0.01

Ovarian volume (ml)

1.7 ± 0.7

1.8 ± 0.5

NS

Uterine length (cm)

3.7 ± 1.2

3.4 ± 1

NS

Metabolic profile

   

Fasting glucose (mg/dl)

73.3 ± 8.5

80.2 ± 10.2

0.04

Total Cholesterol (mg/dl)

158.6 ± 31.9

185.6 ± 35.7

0.02

LDL-C (mg/dl)

97 ± 35.1

113.2 ± 17.6

NS

HDL-C (mg/dl)

45 ± 8.9

53 ± 9.1

NS

TGR (mg/dl)

89.8 ± 46.7

104.8 ± 48.8

NS

TGR/HDL-C ratio

2.2 ± 0.9

1.5 ± 0.5

NS

  1. Data are displayed as mean (± SDS). BMI, body mass index; DHEAS, dehydroepiandrosterone sulfate; LH, luteinizing hormone; FSH, follicle-stimulating hormone; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; TGR, Triglycerides.